Spotlight On 3 Penny Stocks With Market Caps Over $100M

In the last week, the market has been flat, though it is up 10.0% over the past year with earnings forecast to grow by 17% annually. In such a climate, identifying stocks that combine value and potential growth can be particularly rewarding. Penny stocks, often associated with smaller or newer companies, still hold significant promise when backed by strong financials and growth prospects.

We're going to check out a few of the best picks from our screener tool.

Anixa Biosciences (ANIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines targeting critical unmet needs in oncology, with a market cap of $114.03 million.

Operations: Anixa Biosciences, Inc. currently does not report any revenue segments.

Market Cap: $114.03M

Anixa Biosciences, with a market cap of US$114.03 million, is a pre-revenue biotechnology company focusing on innovative cancer therapies. Its financial position is stable, with short-term assets of US$14.9 million covering both short and long-term liabilities effectively. The management team is experienced, averaging 9.3 years in tenure, and the board's expertise further strengthens its strategic direction. Recent clinical trial progress for its FSHR-targeted CAR-T therapy shows promising safety and survival outcomes without dose-limiting toxicities in ovarian cancer patients, indicating potential future breakthroughs despite current unprofitability and ongoing net losses reported at US$2.61 million for Q3 2026.

• Take a closer look at Anixa Biosciences' potential here in our financial health report.
• Gain insights into Anixa Biosciences' future direction by reviewing our growth report.

Enovix (ENVX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Enovix Corporation designs, develops, and manufactures lithium-ion battery cells both in the United States and internationally, with a market cap of approximately $716.94 million.

Operations: The company generates revenue primarily from its Batteries / Battery Systems segment, totaling $35.88 million.

Market Cap: $716.94M

Enovix, with a market cap of US$716.94 million, is navigating challenges typical of penny stocks, including high volatility and unprofitability. Its debt to equity ratio has increased significantly over five years, yet the net debt to equity remains satisfactory at 26.3%. The company’s short-term assets exceed liabilities by a substantial margin but do not cover long-term liabilities. Despite ongoing losses and negative return on equity (-80.26%), Enovix's strategic expansion in South Korea aims to double production capacity for its battery products by mid-2027, supported by recent purchase orders from the defense sector and completed share buybacks worth US$64.49 million.

• Navigate through the intricacies of Enovix with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into Enovix's future.

Under Armour (UAA)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Under Armour, Inc. designs, develops, markets, and distributes performance apparel, footwear, and accessories for men, women, and youth with a market cap of approximately $1.98 billion.

Operations: Under Armour generates its revenue across several regions, with North America contributing $2.80 billion, Europe, The Middle East and Africa (EMEA) accounting for $1.21 billion, Asia-Pacific bringing in $708.33 million, and Latin America adding $238.37 million.

Market Cap: $1.98B

Under Armour, with a market cap of US$1.98 billion, faces challenges typical of penny stocks, including unprofitability and negative operating cash flow. The company's net debt to equity ratio is satisfactory at 13.7%, and short-term assets exceed both short-term and long-term liabilities. Recent developments include lowered earnings guidance due to softer demand in key regions like North America and Asia-Pacific, alongside a shelf registration filing for $101.6 million in stock offerings. Despite these hurdles, Under Armour's management team and board are experienced, with average tenures of 2.9 years and 5.1 years respectively.

• Get an in-depth perspective on Under Armour's performance by reading our balance sheet health report here.
• Understand Under Armour's earnings outlook by examining our growth report.

Make It Happen

• Investigate our full lineup of 324 US Penny Stocks right here.
• Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com